March 2, 2021, Vol 325, No. 9, Pages 805-898
Funding of Pharmaceutical Innovation During and After the COVID-19 Pandemic
James C. Robinson, PhD, MPH
free access has active quiz has audio
JAMA. 2021;325(9):825-826. doi:10.1001/jama.2020.25384
This Viewpoint considers whether the shift away from private investment toward government funding of drug and vaccine development and commercialization during the coronavirus disease 2019 (COVID-19) pandemic is sustainable, arguing that the same or greater level of public investment will be necessary if drug prices are to remain affordable and if the US wants to maintain its global leadership position.
Conversations with Dr Bauchner: Funding of Pharmaceutical Innovation During and After the COVID-19 Pandemic